HY 088
Alternative Names: HY-088Latest Information Update: 26 Apr 2023
At a glance
- Originator Hyloris Pharmaceuticals
- Class Phosphates
- Mechanism of Action Phosphate replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Hyperphosphataemia
Most Recent Events
- 03 Apr 2023 Early research in Hyperphosphataemia in Belgium (PO) (Hyloris Pharmaceuticals pipeline, April 2023)